EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care

Abhenil Mittal iD, Srikala S Sridhar, Michael Ong, Di Maria Jiang iD

Current Oncology · 2023

DOI: 10.3390/curroncol30040332 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology, 2023. Verfasst von Abhenil Mittal und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, Toronto, ON M5G 2C1, Can…. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment paradigm for metastatic castrate-sensitive prostate cancer (mCSPC) has evolved rapidly in the past decade with the approval of several life-prolonging therapies including docetaxel chemotherapy and multiple androgen receptor pathway inhibitors (ARPI) in combination with androgen deprivation therapy (ADT). Recently reported phase-three trials have demonstrated a survival benefit of upfront triplet therapy with ADT, docetaxel plus either abiraterone acetate or darolutamide when compared to ADT plus docetaxel alone. However, multiple questions including the incremental benefit of docetaxel to a combination of ADT and ARPI, the timing of ARPI, optimal patient selection for triplet therapy and clinical and genomic biomarkers still remain to be answered. Moreover, real-world data suggest suboptimal treatment intensification with many patients treated with ADT alone highlighting challenges in implementation. In this article, we review the phase-three data associated with triplet therapy in mCSPC. We also discuss the knowledge gaps that exist despite the completion of these studies and how ongoing studies are likely to change the paradigm in the near future. Finally, we provide a simple algorithm based on current data that clinicians can use in daily practice to select patients for appropriate treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsMaleHumansDocetaxelAndrogen AntagonistsStandard of CareAbiraterone Acetate

Stichwörter der Autor:innen

abirateroneandrogen receptor pathway inhibitorsdarolutamidedocetaxelmetastatic castrate sensitive prostate cancertriplet therapy

Substanzen

DocetaxelAndrogen AntagonistsAbiraterone Acetate

Autor:innen und Institutionen

  • Division of Medical Oncology and Hematology, Department of Medicine, Princess Margaret Cancer Center, University of Toronto, Toronto, ON M5G 2C1, Canada.
  • Division of Medical Oncology, The Ottawa Hospital Cancer Centre, University of Ottawa, Ottawa, ON K1H 8L6, Canada.

ORCID-Profile: Abhenil Mittal, Di Maria Jiang

Zitieren

APA

Mittal, A., Sridhar, S. S., Ong, M., & Jiang, D. M. (2023). Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care. Current Oncology. https://doi.org/10.3390/curroncol30040332

Vancouver

Mittal A, Sridhar SS, Ong M, Jiang DM. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care. Current Oncology. 2023. doi:10.3390/curroncol30040332

BibTeX
@article{Mittal2023,
  author = {Mittal, Abhenil and Sridhar, Srikala S and Ong, Michael and Jiang, Di Maria},
  title = {Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30040332}
}
Kostenlos starten →